EUVIMEDEUVIMED entdecken
Crossref

Nuevas metas terapéuticas en el tratamiento de las dislipemias: colesterol no HDL y remanentes de colesterol

Máxima Mendez-Castillo, María Alexandra López, Persio López, Pedro W Díaz Ruiz

Revista de la Federación Argentina de Cardiología · 2024

DOI: 10.63600/01we1f56 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista de la Federación Argentina de Cardiología, 2024. Verfasst von Máxima Mendez-Castillo und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-HDL-C is a powerful indicator of lipoproteins rich in ApoB. Its measurement is much simpler, it does not require fasting to quantify it, not being influenced by triglyceride levels, and it is an excellent marker of atherogenic cholesterol, with a better correlation with cardiovascular risk than LDL-C. In patients in high risk of atherogenic dyslipidemia, the strategy of consideringnon-HDL-C as a primary objective is allowed, because it incorporates the risk of lipid origin better than LDL-C and because it is more feasible than measuring ApoB. The therapeutic objective of non-HDL-C is to add 30 mg/dL to the calculated LDL-C target value; in the general population, optimal non-HDL-C levels of less than 130 mg/dL are maintained. In a patient considered in very high risk, the target LDL-C is less than 55 mg/dL; thus their non-HDL-C should not exceed 85 mg/dL. Non-HDL cholesterol becomes an excellent indicator of total atherogenic cholesterol. And it is a primary therapeutic objective in individuals with atherogenic dyslipidemia. Evidence available to date shows the benefit of adding ethyl eicosapentaenoic acid to patients with elevatednon-HDL cholesterol under optimal treatment with statins, for reducing cardiovascular risk. Fibrates may be considered in patients with extreme hypertriglyceridemia.

Zitieren

APA

Mendez-Castillo, M., López, M. A., López, P., & Ruiz, P. W. D. (2024). Nuevas metas terapéuticas en el tratamiento de las dislipemias: colesterol no HDL y remanentes de colesterol. Revista de la Federación Argentina de Cardiología. https://doi.org/10.63600/01we1f56

Vancouver

Mendez-Castillo M, López MA, López P, Ruiz PWD. Nuevas metas terapéuticas en el tratamiento de las dislipemias: colesterol no HDL y remanentes de colesterol. Revista de la Federación Argentina de Cardiología. 2024. doi:10.63600/01we1f56

BibTeX
@article{MendezCastillo2024,
  author = {Mendez-Castillo, Máxima and López, María Alexandra and López, Persio and Ruiz, Pedro W Díaz},
  title = {Nuevas metas terapéuticas en el tratamiento de las dislipemias: colesterol no HDL y remanentes de colesterol},
  journal = {Revista de la Federación Argentina de Cardiología},
  year = {2024},
  doi = {10.63600/01we1f56}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche